Comprehensive Report on the Investigational Drug LY-3938577

1. Executive Summary

LY-3938577 is an investigational biological product currently under development by Eli Lilly and Company. It is in Phase I clinical trials for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).[1] The primary innovation of LY-3938577 lies in its proposed mechanism of action, which involves targeting a "glucose sensing insulin receptor".[1] This suggests a novel therapeutic approach aimed at achieving more physiological glucose regulation than current insulin therapies.

The clinical development program is actively progressing, with two key Phase I studies identified: NCT06132126, which has been completed, and NCT06280703, which is currently recruiting participants.[1] These trials are crucial for assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY-3938577.

The decision by Eli Lilly and Company to pursue development for both T1DM and T2DM concurrently from the initial Phase I stages is noteworthy. T1DM is primarily an autoimmune condition leading to absolute insulin deficiency, whereas T2DM involves a complex interplay of insulin resistance and progressive beta-cell dysfunction. While both conditions may ultimately require insulin therapy, their underlying pathophysiologies differ significantly. The simultaneous development for both types suggests a strong belief in the broad applicability of LY-3938577's glucose-sensing mechanism. This approach implies that the core innovation – glucose-responsive activity – is perceived as a fundamental improvement to insulin therapy itself, offering benefits such as enhanced safety (e.g., reduced risk of hypoglycemia) and more physiological glycemic control, which are relevant to any patient requiring insulin, irrespective of the diabetes type. Such a strategy for a novel agent is ambitious and indicates considerable confidence in the potential of the glucose-sensing paradigm.

If LY-3938577 successfully navigates clinical development, it could represent a significant advancement in diabetes management, offering the potential for improved glycemic control while mitigating the risk of hypoglycemia, a major concern with conventional insulin treatments.

2. Introduction to LY-3938577

2.1. The Unmet Need in Diabetes Management

Diabetes mellitus, encompassing both Type 1 and Type 2, represents a significant and growing global health burden. While insulin therapy has been a cornerstone of diabetes management for a century, current insulin treatments possess inherent limitations. A primary concern is the risk of iatrogenic hypoglycemia, which can have severe consequences for patients. Furthermore, the complexity of many insulin regimens, requiring careful dose adjustments and frequent monitoring, imposes a considerable burden on individuals with diabetes. Achieving a truly physiological insulin profile that mimics the precise, glucose-responsive secretion of endogenous pancreatic insulin remains a formidable challenge. These limitations underscore the persistent unmet medical need for novel insulin therapies that can offer improved glycemic control with enhanced safety and convenience.

2.2. LY-3938577: An Investigational Agent from Eli Lilly and Company

LY-3938577 is an investigational therapeutic agent being developed by Eli Lilly and Company.[1] Eli Lilly has a long and distinguished history in the field of diabetes care, being one of the first companies to commercially produce insulin. Their continued investment in innovative diabetes therapies, such as LY-3938577, highlights their commitment to addressing the evolving needs of patients with diabetes.

2.3. The Promise of "Smart Insulins": The Glucose-Sensing Paradigm

LY-3938577 is conceptualized as a "glucose-sensing" or "glucose-responsive" insulin.[1] This paradigm, often referred to as "smart insulin" technology, involves engineering insulin molecules or insulin delivery systems that can modulate their glucose-lowering activity in direct response to ambient blood glucose concentrations.[1] The fundamental goal is to create an insulin therapy that more closely mimics the physiological function of pancreatic beta cells, which release insulin in proportion to blood glucose levels.

The potential benefits of such a system are substantial. By increasing insulin activity when glucose levels are high and decreasing activity when glucose levels are low, a glucose-sensing insulin could significantly reduce the risk of hypoglycemia, a major fear and a dangerous complication for insulin-treated patients. This could, in turn, lead to improved time-in-therapeutic-range for blood glucose, better overall glycemic control (e.g., lower HbA1c), and potentially a simplification of complex insulin regimens, thereby improving the quality of life for individuals with diabetes.

Eli Lilly's strategic commitment to this innovative area is further evidenced by its acquisition of Protomer Technologies in 2021.[22] Protomer was a preclinical-stage company specifically focused on developing glucose-responsive insulins that can sense glucose levels and automatically adjust their activity. While it is not explicitly stated that LY-3938577 originates directly from Protomer's platform, this acquisition underscores Lilly's strategic investment in and pursuit of "smart insulin" technologies.

The advancement of LY-3938577 into Phase I clinical trials by a major pharmaceutical company like Eli Lilly is a significant step in the field of "smart insulins." The concept of glucose-responsive insulin has been an aspirational goal in diabetes research for several decades, with mentions of such research dating back to the 1970s.[22] However, the development of clinically viable smart insulins has been fraught with substantial technical challenges, including achieving the requisite speed and sensitivity of glucose response, ensuring the biocompatibility of the sensing and delivery components, and overcoming manufacturing complexities.[22] Lilly's decision to progress LY-3938577 into human trials suggests a degree of confidence that their proprietary approach to this candidate may have overcome some of these long-standing hurdles. This endeavor is not merely an incremental improvement over existing therapies but represents a potential paradigm shift in insulin treatment, carrying both high risk, due to the novelty and historical difficulties, and high reward, in terms of clinical and commercial impact.

The specific terminology used to describe LY-3938577's target as a "glucose sensing insulin receptor" [1] is noteworthy. The canonical insulin receptor is activated by insulin binding, and its signaling pathway is not typically described as directly sensing glucose to modulate its response to already-bound insulin. This suggests that LY-3938577 is likely an engineered insulin molecule or conjugate that possesses its own glucose-sensing moiety, which then influences its interaction with, or activation of, the standard insulin receptor in a glucose-dependent manner. This interpretation aligns more closely with established "smart insulin" concepts, where the insulin molecule itself is modified to exhibit glucose-responsive activity.[2] The classification of LY-3938577's mechanism of action as "Undefined mechanism" by AdisInsight [3] further underscores the proprietary and novel nature of its precise molecular interactions, which are not yet fully disclosed in the public domain.

3. Pharmacological Profile

3.1. Drug Class

LY-3938577 is classified as an antihyperglycaemic agent, reflecting its primary therapeutic goal of lowering blood glucose levels in individuals with diabetes.[3] It is further identified as a "biological product".[4] This classification indicates that LY-3938577 is likely a macromolecule, such as an engineered protein or peptide, rather than a chemically synthesized small molecule. This aligns with its conceptualization as a modified insulin or insulin-like therapeutic.

The designation as a biological product carries specific implications. The manufacturing processes for biologics are generally more complex and costly than those for small molecules. There is also a potential for immunogenicity, where the patient's immune system may react to the biological agent. Furthermore, the regulatory approval pathway for biological products (e.g., Biologics License Application - BLA in the United States) differs from that for small-molecule drugs. These factors are important considerations throughout the development lifecycle of LY-3938577. The biological nature of the product is consistent with the sophisticated protein engineering or conjugation strategies typically required to imbue an insulin molecule with glucose-sensing properties.

3.2. Mechanism of Action (MoA)

The proposed mechanism of action for LY-3938577 involves targeting a "glucose sensing insulin receptor" or acting as a "GS insulin receptor agonist".[1] This implies that LY-3938577's ability to activate the insulin receptor and subsequently elicit glucose-lowering effects is dynamically modulated by ambient glucose concentrations. In theory, higher glucose levels would lead to greater insulin action, while lower glucose levels would result in diminished action, thereby creating a self-regulating system aimed at minimizing the risk of hypoglycemia.

The insulin receptor (INSR), also known as CD220, is a well-characterized tyrosine kinase receptor that mediates the metabolic effects of insulin.[36] The novel aspect of LY-3938577 is the "glucose-sensing" component that is integrated into its interaction with this receptor system.

The term "glucose sensing insulin receptor agonist" [19] provides a more specific insight into its function. An agonist is a substance that binds to a receptor and activates it to produce a biological response. This suggests that LY-3938577 directly activates the insulin receptor, initiating the downstream signaling cascade responsible for glucose uptake and metabolism, similar to endogenous insulin or conventional insulin analogs. The "glucose-sensing" characteristic implies that the potency of this agonism, or the kinetics of its binding and activation of the insulin receptor, is variable and dependent on glucose levels. This could be achieved, for example, if glucose binding to a specific moiety on the LY-3938577 molecule (or a complex it forms) allosterically modulates its conformation, thereby altering its affinity or efficacy at the insulin receptor. Such a mechanism would require sophisticated molecular engineering.

It is important to note that AdisInsight currently lists the mechanism of action for LY-3938577 as "Undefined mechanism".[3] This likely reflects the early stage of development and the proprietary nature of the detailed molecular interactions, which have not yet been fully disclosed by Eli Lilly in peer-reviewed publications or detailed regulatory documents.

3.3. Pharmacodynamics (PD)

The primary pharmacodynamic effect of LY-3938577 is expected to be glucose-lowering. A key objective of the ongoing clinical trial NCT06280703 (specifically Parts B and C) is to meticulously evaluate the blood sugar lowering effect and the duration of action of LY-3938577 in participants with Type 1 Diabetes Mellitus.[5] This evaluation will involve the use of euglycemic and hyperglycemic clamp techniques, which are considered gold-standard methods for assessing insulin action and sensitivity in vivo.

The use of these sophisticated clamp techniques in an early Phase I study signifies a rigorous approach by Eli Lilly to quantify the glucose-dependent activity profile of LY-3938577 from the outset. Euglycemic clamps, for instance, measure the amount of glucose that must be infused to maintain normal blood glucose levels while a specific rate of an insulin-like drug is administered, providing a direct measure of insulin sensitivity and action. Hyperglycemic clamps assess insulin secretion in response to elevated glucose, but in the context of an exogenous insulin-like agent such as LY-3938577, these clamps would help characterize its activity under high glucose conditions.

In the NCT06280703 study, LY-3938577 will be compared to Insulin Degludec, an ultra-long-acting basal insulin analog known for its relatively flat and prolonged action profile.[5] This comparison is critical. If LY-3938577 demonstrates a greater glucose-lowering effect at high glucose concentrations and a reduced effect at euglycemic or hypoglycemic levels compared to Insulin Degludec (which exhibits relatively constant action irrespective of glucose fluctuations within a certain range), it would provide strong evidence supporting the "glucose-sensing" mechanism and its potential clinical advantages.

4. Clinical Development Program

4.1. Overview

LY-3938577 is currently in Phase I of clinical development.[1] The program is investigating the compound for the treatment of both Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).[1] The routes of administration being explored are intravenous (IV) and subcutaneous (SC).[1]

4.2. Summary of Clinical Trials

The following table summarizes the key publicly available information on the clinical trials for LY-3938577:

NCT Identifier	Official Trial Title	Phase	Status	Condition(s) Studied	Key Interventions	Primary Purpose(s)	Sponsor	Key Locations	Target Enrollment	Study Start Date	Estimated/Actual Completion Date
NCT06132126	A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus (J4P-MC-IYAA)	Phase I	Completed	Healthy Volunteers, Type 2 Diabetes Mellitus	LY3938577 (SC), Placebo (SC), Insulin degludec (SC)	Safety, Tolerability, PK	Eli Lilly and Company	USA	66	Nov 17, 2023	Jun 28, 2024 (Actual)
NCT06280703	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (J4P-MC-IYAB) / A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C) Study...	Phase I	Recruiting	Healthy Volunteers, Type 1 Diabetes Mellitus	LY3938577 (IV, SC), Placebo (IV, SC), Insulin degludec (IV, SC), Insulin lispro (IV)	Safety, Tolerability, PK, PD (glucose-lowering)	Eli Lilly and Company	Germany	70	May 15, 2024	Oct 2025 (Estimated)

Data synthesized from multiple sources including.[1]

4.3. Detailed Review of Clinical Trial NCT06132126

Official Title: "A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus" (also referred to as "A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus").4

Status: Completed. The primary completion date was June 28, 2024.3 MedPath last updated information on July 24, 2024.5

Sponsor: Eli Lilly and Company.4

Phase: I.1

Brief Summary: The study was designed to assess the safety and tolerability of single doses (Part A) and multiple ascending doses (Part B) of LY-3938577.4

Study Design: This was a single and multiple-ascending dose study with a primary purpose of evaluating safety, tolerability, and pharmacokinetics.4

Participant Population: Healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) were enrolled.4 The target enrollment was 66 participants.5 Key eligibility criteria included general good health for healthy volunteers, a diagnosis of T2DM for at least one year for patients, and stable body weight for at least 90 days prior to screening.13

Interventions:

• Part A (Single Dose): LY3938577 administered subcutaneously (SC), Placebo administered SC, Insulin degludec administered SC.[8]
• Part B (Multiple Doses, T2DM): LY3938577 administered SC.[8] Primary Outcome Measures:
• Assessment of safety and tolerability (e.g., incidence and severity of adverse events).
• Pharmacokinetic parameters of LY-3938577 (e.g., maximum concentration (Cmax​), area under the concentration-time curve (AUC)). Locations: The study was conducted at sites in the United States, including Labcorp CRU in Dallas, TX; Qps-Mra, Llc in Miami, FL; and CenExel ACT in Anaheim, CA.[5] Results/Publications: As of the latest information available (July 2024), the trial has been completed. However, specific results or publications arising from this study have not yet been listed in the public domain.[11]

The completion of the NCT06132126 study is a pivotal development. The data generated from this trial, covering safety, tolerability, and pharmacokinetic profiles after both single and multiple subcutaneous doses in healthy individuals and patients with T2DM, are fundamental for Eli Lilly's decision-making process regarding the continued development of LY-3938577. This dataset will inform dose selection for subsequent Phase II trials and provide the initial human safety and PK characteristics for the subcutaneous route of administration. The comparison with insulin degludec, even if limited to a specific part of the study, will offer an early, albeit preliminary, benchmark for LY-3938577's profile. It is standard practice for pharmaceutical companies to thoroughly analyze Phase I data before public disclosure, typically at scientific conferences or in peer-reviewed journals; such results for NCT06132126 may be anticipated in late 2024 or 2025.

4.4. Detailed Review of Clinical Trial NCT06280703

Official Title: "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)" (also referred to as "A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus").4

Status: Recruiting.2 The estimated study completion date is October 2025.12

Sponsor: Eli Lilly and Company.4

Phase: I.2

Brief Summary: The study aims to evaluate the pharmacokinetics (amount of LY-3938577 in the bloodstream and its elimination), pharmacodynamics (glucose-lowering effect and duration of action compared to Insulin Degludec in T1DM patients), safety, and tolerability of LY-3938577.5

Study Design: This is a three-part (A, B, and C) study. Part A is randomized and double-blind (LY-3938577 versus Placebo). Parts B and C are open-label. The study includes multi-dose elements and is designed primarily for basic science (PK/PD characterization), safety, and tolerability assessment.4

Participant Population: Healthy participants will be enrolled in Part A, while participants with T1DM will be enrolled in Parts B and C. The target enrollment is 70 participants, aged 18 to 64 years.4

* Eligibility 5:

* Part A: Overtly healthy individuals.

* Parts B and C (T1DM): Diagnosis of T1DM for at least 2 years, fasting C-peptide ≤ 0.20 nmol/L (or non-fasting ≤ 0.30 nmol/L), HbA1c between 6.0% and 8.5%, insulin pump users with total daily basal dose 15-45 IU.

* All Parts: Normal blood pressure, pulse, acceptable safety labs, BMI 18.0-35.0 kg/m$^2$, sufficient venous access.

* Exclusion criteria include recent treatment with GLP-1 RAs, DPP4 inhibitors, GIP agonists, metformin, or SGLT2 inhibitors (within 3 months); history of renal transplantation, dialysis, serum creatinine >2.00 mg/dL, or eGFR <60 mL/min/1.73m$^2$; acute or chronic hepatitis or other significant liver disease (except NAFLD); elevated liver enzymes (TBL >2x ULN, ALT/AST >2.5x ULN).

Interventions 5:

• Part A Period 1 (Healthy): Single IV dose of LY3938577 or Placebo.
• Part A Period 2 (Healthy): Single SC dose of LY3938577 or Placebo.
• Part B (T1DM): Single IV doses of LY3938577 or Insulin Degludec (during euglycemic and hyperglycemic clamps, with Insulin Lispro for basal coverage).
• Part C (T1DM): Two SC doses of LY3938577 or Insulin Degludec. Primary Outcome Measures [5]:
• Pharmacokinetics of LY-3938577 (e.g., Cmax​, AUC).
• Number of participants with adverse events. Secondary Outcome Measures [5]:
• Pharmacodynamic parameters related to glucose control (e.g., glucose infusion rate during clamps, changes in blood glucose). Locations: Germany (Profil Institut für Stoffwechselforschung, Neuss).[5] Results/Publications: This trial is currently recruiting; no results or publications are yet available.

The design of NCT06280703 is particularly informative. The inclusion of both healthy volunteers and patients with T1DM allows for a comprehensive early assessment of LY-3938577. The use of euglycemic and hyperglycemic clamps in T1DM patients is a robust method to directly assess the glucose-lowering activity and, crucially, the glucose-responsiveness of LY-3938577. Comparing its pharmacodynamic profile under these controlled conditions against Insulin Degludec, a well-characterized ultra-long-acting basal insulin, will be key to understanding if LY-3938577 can indeed offer a more physiological, "smarter" insulin action. The focus on T1DM, a condition of absolute insulin deficiency, will allow for a clearer assessment of LY-3938577's intrinsic properties without the confounding factor of endogenous insulin secretion or significant insulin resistance seen in many T2DM patients.

4.5. Regulatory Status and Designations

Currently, there is no information in the provided materials to suggest that LY-3938577 has received any specific regulatory designations, such as Orphan Drug Designation, from major regulatory authorities like the FDA or EMA.[4] Given that T1DM and T2DM are prevalent conditions, Orphan Drug Designation would generally not be applicable unless a very specific, rare sub-population of diabetes was being targeted, which is not indicated by the current trial designs. Interactions with regulatory agencies regarding the development plan are standard but not typically made public at this early stage.

4.6. Patents

While Eli Lilly and Company holds numerous patents related to diabetes treatments and insulin analogs, specific patents definitively covering the exact molecular structure or composition of LY-3938577 are not explicitly detailed in the provided research snippets.[2] Patent applications such as WO2015051052A2/A3 and WO2016179568A1 discuss glucose-responsive insulin conjugates [30], and US20210069286A1 concerns larazotide for hyperglycemia [47]; however, their direct and specific linkage to LY-3938577 is not confirmed by the available information. The proprietary nature of novel drug candidates often means that specific structural and compositional patent details become fully public or are definitively linked to a development code at a later stage.

4.7. Conference Presentations

As of the information available up to early 2025, there are no specific conference presentations (e.g., at ADA, EASD, Endocrine Society, ATTD) detailing clinical trial results for LY-3938577.[16] This is consistent with the early phase of its clinical development program. Pharmaceutical companies typically present Phase I data after completion and thorough analysis, often at major scientific meetings.

The lack of detailed structural patents specifically linked to LY-3938577 or specific conference presentations detailing its results by mid-2024/early-2025, despite Phase I trials being active or completed, is characteristic of the early stages of pharmaceutical development. Companies often maintain tight control over proprietary information regarding novel candidates until more substantial clinical data packages are assembled or strategic disclosures are planned.

5. Chemical and Physical Properties

LY-3938577 is also referred to by the alternative name LY3938577.[5] As a biological product [4], detailed chemical properties such as a specific CAS (Chemical Abstracts Service) registry number, definitive molecular formula, and exact molecular weight are not publicly available in the provided research materials.[4] Similarly, the precise amino acid sequence or structural details of this engineered biological molecule have not been disclosed.[4]

The absence of such specific identifiers and structural information is common for proprietary biological therapeutics in early-phase clinical development. This information is typically revealed at later stages of development or in patent disclosures that can be definitively linked to the specific clinical candidate.

6. Preclinical Data

Specific preclinical study results for LY-3938577, such as in vitro characterization of its glucose-sensing mechanism or efficacy data from animal models of diabetes, are not extensively detailed in the provided research snippets.[7] While the general concept of glucose-responsive insulins has been explored preclinically by various research groups and companies, including Eli Lilly through its acquisition of Protomer Technologies [2], the direct preclinical data package that supported the Investigational New Drug (IND) application for LY-3938577 itself is not publicly available. It is standard for pharmaceutical companies to have a comprehensive internal preclinical dossier demonstrating proof-of-concept, efficacy, and safety in relevant models before advancing a candidate to human trials.

7. Discussion and Future Outlook

LY-3938577 represents a potentially transformative approach to insulin therapy. Its development as a glucose-sensing insulin receptor agonist by Eli Lilly and Company addresses a long-standing goal in diabetes care: to create an insulin that can automatically adjust its activity based on real-time blood glucose levels. This could lead to more stable glycemic control, a significant reduction in the risk of hypoglycemia, and an overall decrease in the daily management burden for individuals with both Type 1 and Type 2 diabetes.

The progression of LY-3938577 through Phase I clinical trials, particularly the ongoing NCT06280703 study with its rigorous pharmacodynamic assessments using euglycemic and hyperglycemic clamps, will be critical in validating its proposed mechanism of action. The results from these early human studies will provide the first insights into whether the glucose-sensing properties observed or hypothesized in preclinical settings translate to a clinically meaningful effect in humans. Key questions will revolve around the sensitivity and responsiveness of LY-3938577 to varying glucose concentrations, its duration of action, and its safety and tolerability profile.

The development of "smart insulins" has historically been challenging due to the complexity of designing molecules that can accurately sense glucose and modulate insulin activity appropriately, maintain stability, avoid immunogenicity, and be manufacturable at scale. Eli Lilly's advancement of LY-3938577 suggests that they have potentially overcome some of these significant hurdles. Their acquisition of Protomer Technologies further signals a strategic commitment to this area of innovation.[22]

The competitive landscape for diabetes therapies is dynamic, with ongoing advancements in conventional insulins, GLP-1 receptor agonists, SGLT2 inhibitors, and other novel mechanisms. For LY-3938577 to make a significant impact, it will need to demonstrate clear clinical advantages over existing and emerging treatments, particularly in terms of safety (hypoglycemia reduction) and glycemic control (e.g., improved time in range, HbA1c reduction without increased hypoglycemia). While Novo Nordisk has also been active in researching glucose-sensitive insulins, such as NNC2215 (a research compound) [20], the direct competitive positioning will become clearer as more clinical data for LY-3938577 emerges.

The successful development of LY-3938577 could profoundly alter the treatment landscape for diabetes. For individuals with T1DM, it could offer a basal insulin replacement that inherently adjusts to glucose fluctuations, potentially simplifying management and improving safety. For individuals with T2DM requiring insulin, it could provide a safer and more effective option, particularly for those at high risk of hypoglycemia. However, the journey for such a novel biologic is extensive. Beyond demonstrating efficacy and safety in larger and longer-term Phase II and III trials, challenges related to scalable and cost-effective manufacturing, as well as establishing its value proposition to payers and healthcare systems, will need to be addressed.

8. Conclusion

LY-3938577 is an early-stage investigational biological product from Eli Lilly and Company, designed as a glucose-sensing insulin receptor agonist for the treatment of Type 1 and Type 2 Diabetes Mellitus. Its core innovation lies in the potential to provide glucose-responsive insulin activity, aiming to improve glycemic control while minimizing the risk of hypoglycemia.

Currently in Phase I clinical development, with one study completed (NCT06132126) and another actively recruiting and conducting detailed pharmacodynamic assessments (NCT06280703), LY-3938577 is at a crucial juncture. The forthcoming results from these initial human trials will be paramount in determining its safety, tolerability, pharmacokinetic profile, and, most importantly, whether its glucose-sensing mechanism translates into a clinically meaningful and differentiated therapeutic effect.

While the path for such a novel "smart insulin" is inherently challenging, the potential benefits for patients with diabetes are substantial. The commitment of a major pharmaceutical company like Eli Lilly to this advanced therapeutic concept underscores the significance of this development program. Future updates on clinical trial outcomes and further elucidation of its precise mechanism of action will be critical in shaping the future trajectory of LY-3938577.

References

• [1]: GlobalData. Likelihood of Approval and Phase Transition Success Rate Model - LY-3938577 in Type 2 Diabetes.
• [2]: Pharmaceutical Technology. LY-3938577 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval.
• [3]: AdisInsight. LY 3938577. (09 Aug 2024).
• [7]: Lilly Trials. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM).
• [56]: Pharmaceutical Technology. Data Insights.
• [36]: ACROBiosystems. Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified).
• [8]: Veeva CTV. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus.
• [6]: Clinical Digest. Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials. (20 May 2025).
• [9]: DrugBank. Type 2 Diabetes Completed Phase 1 Trials for Insulin degludec (DB09564).
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents.
• [5]: MedPath. LY-3938577.
• [10]: Veeva CTV. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM).
• [37]: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified). (Spanish site)
• [3]: AdisInsight. LY 3938577..[3]
• [19]: PhRMA. Medicines in Development: Preventive Treatments. (September 15, 2024).
• [47]: Patents.google.com. US20210069286A1 - Compositions and methods for treating hyperglycemia and associated conditions.
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [1]: GlobalData. Likelihood of Approval and Phase Transition Success Rate Model - LY-3938577 in Type 2 Diabetes..[1]
• [5]: MedPath. LY-3938577..[5]
• [54]: Lilly Medical. EASD 2024 Presentations. (September 10, 2024).
• [55]: Lilly Medical. EASD 2023 Presentations. (October 2, 2023 - October 6, 2023).
• [48]: The Motley Fool. Eli Lilly (LLY) Q4 2023 Earnings Call Transcript. (February 6, 2024).
• [49]: Investing.com. Earnings Call: Eli Lilly Reports Robust Growth and Pipeline Progress. (February 7, 2024).
• [6]: Clinical Digest. Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials..[6]
• [50]: DrugPatentWatch. Eli Lilly And Company - Patents by Applicant.
• [14]: DrugBank. Type 1 Diabetes Mellitus (DBCOND0029465).
• [37]: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified)..[37]
• [41]: Lilly Investor Relations. Q1 2024 Earnings Presentation.
• [5]: MedPath. LY-3938577..[5]
• [10]: Veeva CTV. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)..[10]
• [30]: Patents.google.com. WO2015051052A2 - Glucose-responsive insulin conjugates.
• [35]: Patents.google.com. WO2015051052A3 - Glucose-responsive insulin conjugates.
• [38]: ACROBiosystems. Insulin R Protein..[36]
• 39: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified)..[37]
• [40]: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified)..[40]
• [5]: MedPath. LY-3938577..[5]
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [14]: DrugBank. Type 1 Diabetes Mellitus (DBCOND0029465)..[14]
• [38]: ACROBiosystems. Insulin R Protein..[36]
• [57]: NIH RePORTER. Elucidating the pharmacogenetics of the response to GLP-1 receptor agonists for type 2 diabetes.
• [18]: PublicNow. q1 2025 earnings call.
• [11]: MedPath. Insulin Degludec.
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [12]: Lilly Trials. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) - NCT06280703.
• [10]: Veeva CTV. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)..[10]
• [19]: PhRMA. Medicines in Development: Preventive Treatments..[19]
• [5]: MedPath. LY-3938577..[5]
• [2]: Pharmaceutical Technology. LY-3938577 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval..[2]
• [7]: Lilly Trials. Find Lilly Clinical Trials.
• [58]: Lilly Trials. Completed Trials - Lilly Trials.
• [55]: Lilly Medical. EASD 2023 Presentations..[55]
• [54]: Lilly Medical. EASD 2024 Presentations..[54]
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [51]: Patents.google.com. WO2016179568A1 - Compositions comprising conjugates with modified insulin molecules.
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [37]: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified)..[37]
• [58]: Lilly Trials. Completed Trials - Lilly Trials..[58]
• [63]: PMC. Recent Advances in Glucagon-like Peptide 1 Receptor Agonist-Based Combination Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease. (May 2024).
• [64]: PubMed. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes. (Nov 2022).
• [13]: Lilly Trials. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus - NCT06132126.
• [42]: Otsuka Trials. A Phase 2b, Open-Label Extension Trial to Evaluate Long-Term Safety and Efficacy of Sibeprenlimab in Participants With Immunoglobulin A Nephropathy Who Completed a Prior Sibeprenlimab Study.
• [14]: DrugBank. Type 1 Diabetes Mellitus (DBCOND0029465)..[14]
• [10]: Veeva CTV. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)..[10]
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [6]: Clinical Digest. Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials..[6]
• [20]: Nature. Glucose-sensitive insulin with attenuation of hypoglycaemia. (Oct 2024).
• [21]: Journal of Clinical Endocrinology & Metabolism. Next-Generation Insulin Analogues: A Forward Look. (2022).
• [11]: MedPath. Insulin Degludec.
• [15]: Larvol Sigma. Eli Lilly and Company - Trials.
• [7]: Lilly Trials. Find Lilly Clinical Trials..[7]
• [65]: ACS Publications. Biomimetic Pancreas with Glucose-Responsive Nanoparticles Encapsulating GLP-1 Analogues for Type 1 Diabetes Mellitus Therapy. (May 2024).
• [22]: BioPharma Dive. Lilly wagers up to $1B on a biotech's plan for a new type of insulin. (July 2021).
• [23]: PharmaCompass. Eli Lilly - Drugs in Development.
• [6]: Clinical Digest. Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials..[6]
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [16]: Lilly Investor Relations. Q1 2025 Earnings Call Slides.
• [17]: Lilly Investor Relations. 2024 Integrated Summary Report.
• [24]: MedCity News. Eli Lilly gets glucose-sensing "smart insulin" via buyout of preclinical Protomer. (July 2021).
• [59]: WHO ICTRP. International Clinical Trials Registry Platform.
• [60]: WHO ICTRP. ICTRP Search Portal.
• [5]: MedPath. LY-3938577..[5]
• [1]: GlobalData. Likelihood of Approval and Phase Transition Success Rate Model - LY-3938577 in Type 2 Diabetes..[1]
• [25]: Synapse by PatSnap. What are the key players in the Type 1 Diabetes treatment market?.
• [2]: Pharmaceutical Technology. LY-3938577 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval..[2]
• [43]: Hit Consultant. Eli Lilly’s Oral GLP-1 Shows Positive Phase 3 Results for Type 2 Diabetes. (April 2025).
• [11]: MedPath. Insulin Degludec..[11]
• [12]: Lilly Trials. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) - NCT06280703..[12]
• [5]: MedPath. LY-3938577..[5]
• [26]: Novo Nordisk. Q4 2024 Investor Presentation.
• [27]: Midgard Finance Blog. Novo Nordisk vs. Eli Lilly: Navigating the GLP-1 Tsunami. (May 2025).
• [2]: Pharmaceutical Technology. LY-3938577 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval..[2]
• [35]: Patents.google.com. WO2015051052A3 - Glucose-responsive insulin conjugates..[35]
• [59]: WHO ICTRP. International Clinical Trials Registry Platform..[59]
• [60]: WHO ICTRP. ICTRP Search Portal..[60]
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents..[4]
• [52]: Synapse by PatSnap. Eli Lilly & Co. - Organization Profile.
• [28]: JDRF Canada. Annual Report 2014.
• [29]: Diabetes Research Institute Foundation. Cell-based therapies for type 1 diabetes mellitus. (Sept 2024).
• [53]: Lilly Investor Relations. Q3 2024 Earnings Presentation.
• [5]: MedPath. LY-3938577..[5]
• [59]: WHO ICTRP. International Clinical Trials Registry Platform..[59]
• [30]: Patents.google.com. WO2015051052A2 - Glucose-responsive insulin conjugates..[30]
• [31]: PMC. Next-Generation Insulin Analogues: A Forward Look. (2022).
• [32]: ResearchGate. IMRA Conference Proceedings. (2015).
• [33]: ResearchGate. Emerging Technologies for Diabetes Care. (2018).
• [13]: Lilly Trials. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus - NCT06132126.
• [44]: PublicNow. Q1 2025 Earnings Call Transcript.
• [12]: Lilly Trials. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) - NCT06280703..[12]
• [18]: PublicNow. Q1 2025 Earnings Call Slides.
• [53]: Lilly Investor Relations. Q3 2024 Earnings Presentation..[53]
• [36]: ACROBiosystems. Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified)..[36]
• [53]: Lilly Investor Relations. Q3 2024 Earnings Presentation..[53]
• [16]: Lilly Investor Relations. Q1 2025 Earnings Call Slides..[18]
• [34]: Lilly Investor Relations. Q1 2025 Financial Results Press Release.
• [37]: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified)..[37]
• [36]: ACROBiosystems. Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified)..[36]
• [66]: AdisInsight. LY 3938577. (Inaccessible)
• [61]: ClinicalTrials.gov. NCT06132126. (Inaccessible)
• [62]: ClinicalTrials.gov. NCT06280703. (Inaccessible)
• [61]: ClinicalTrials.gov. NCT06132126. [61]
• [62]: ClinicalTrials.gov. NCT06280703. [62]
• [67]: Lilly Trials. NCT06132126. (Inaccessible)
• [68]: Lilly Trials. NCT06280703. (Inaccessible)
• [61]: ClinicalTrials.gov. NCT06132126. [61]
• [62]: ClinicalTrials.gov. NCT06280703. [62]
• [69]: Lilly Investor Relations. Recent Investor Presentation. (Inaccessible)
• [45]: EMA. Medicines Search. (Inaccessible)
• [46]: FDA. Drug Approvals and Databases.
• [70]: Lilly Investor Relations. Q4 2024 Earnings Call Transcript. (Inaccessible)
• [71]: EMA. Medicines Search. (Inaccessible)
• [72]: FDA. Drugs@FDA Search. (Inaccessible)
• [73]: Lilly Investor Relations. Events and Presentations. (Inaccessible)
• [74]: ADA. Abstracts Archive. (Inaccessible)
• [75]: EASD. EASD 2024 Annual Meeting.
• [76]: Lilly Investor Relations. Annual Reports. (Inaccessible)
• [26]: Novo Nordisk. Q4 2024 Investor Presentation.
• [77]: Lilly Investor Relations. Events and Presentations. (Inaccessible)
• [78]: WHO ICTRP. Trial Search. (Inaccessible)
• [79]: WHO ICTRP. Trial Search for LY-3938577. (Inaccessible)
• [80]: WHO ICTRP. Trial Search for LY3938577. (Inaccessible)

Note: Inaccessible snippets (S_B series) will not be used for content generation but are noted for completeness of the research material list.# Comprehensive Report on the Investigational Drug LY-3938577

1. Executive Summary

LY-3938577 is an investigational biological product developed by Eli Lilly and Company, currently in Phase I clinical development. It is being evaluated for the treatment of both Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).[1] The candidate's proposed mechanism of action involves targeting a "glucose sensing insulin receptor," suggesting a novel approach to insulin therapy designed to offer more physiological glucose regulation.[1]

Two key Phase I clinical trials form the current public basis of its development: NCT06132126, which has been completed, and NCT06280703, which is actively recruiting. These studies aim to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of LY-3938577.[1]

The concurrent development of LY-3938577 for both T1DM and T2DM from the earliest Phase I stages is a notable strategic decision. T1DM arises from autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency, whereas T2DM is characterized by insulin resistance and a progressive decline in beta-cell function. Although both types may necessitate insulin therapy, their underlying pathophysiologies are distinct. Pursuing both indications simultaneously suggests that Eli Lilly perceives the core glucose-sensing mechanism of LY-3938577 as a fundamental improvement to insulin therapy itself, offering broad applicability. This implies the drug is designed to enhance the safety (e.g., by reducing hypoglycemia risk) and efficacy (e.g., by providing more physiological glucose control) of insulin action in a manner relevant to any patient requiring insulin, rather than targeting a defect specific to one type of diabetes. This broad-spectrum approach from an early stage is ambitious and indicates a high degree of confidence in the potential of the glucose-sensing paradigm.

Should LY-3938577 prove successful in its clinical development, it could signify a major advancement in diabetes care, potentially offering patients improved glycemic control with a lower risk of hypoglycemia compared to conventional insulin therapies.

2. Introduction to LY-3938577

2.1. The Unmet Need in Diabetes Management

Diabetes mellitus, encompassing both Type 1 and Type 2, poses a substantial and escalating global health challenge. Insulin therapy, a life-saving treatment for individuals with T1DM and many with advanced T2DM, has been instrumental in diabetes care for over a century. However, conventional insulin therapies are associated with significant limitations. A primary concern is the risk of iatrogenic hypoglycemia, a condition where blood glucose levels fall dangerously low, which can lead to cognitive impairment, seizures, coma, and, in severe cases, death. The fear of hypoglycemia often leads to suboptimal glycemic control as patients and clinicians may aim for higher blood glucose targets. Additionally, many insulin regimens are complex, requiring multiple daily injections, frequent blood glucose monitoring, and meticulous dose adjustments based on food intake, physical activity, and other factors. This complexity places a considerable burden on patients and can impact adherence and quality of life. Furthermore, current exogenous insulin therapies do not perfectly replicate the sophisticated, dynamic glucose-responsive secretion of endogenous insulin by healthy pancreatic beta cells. These limitations highlight a clear and persistent unmet medical need for novel insulin therapies that can provide more effective and safer glycemic control with greater convenience and predictability.

2.2. LY-3938577: An Investigational Agent from Eli Lilly and Company

LY-3938577 is an investigational therapeutic agent currently under development by Eli Lilly and Company.[1] Eli Lilly has a rich legacy in diabetes care, having been one of the pioneering companies in the commercial production of insulin nearly a century ago. The company's continued investment in innovative diabetes treatments, exemplified by the LY-3938577 program, underscores its commitment to addressing the evolving therapeutic needs of the global diabetes population.

2.3. The Promise of "Smart Insulins": The Glucose-Sensing Paradigm

LY-3938577 is being developed based on the principle of a "glucose-sensing" or "glucose-responsive" insulin.[1] This concept, often referred to as "smart insulin" technology, aims to create insulin molecules or insulin-based systems that can autonomously modulate their glucose-lowering activity in direct response to ambient blood glucose concentrations.[1] The overarching goal is to develop an insulin therapy that more faithfully mimics the physiological function of pancreatic beta cells, which intricately adjust insulin secretion based on real-time glucose levels.

The potential advantages of such a system are manifold. A glucose-sensing insulin could theoretically increase its activity when blood glucose levels are elevated (e.g., postprandially) and decrease its activity when glucose levels are normal or low. This self-regulating mechanism holds the promise of significantly reducing the risk of hypoglycemia, which is a major barrier to achieving optimal glycemic control with conventional insulins. Consequently, it could lead to improved time-in-therapeutic-range, better overall glycemic control (as reflected by lower HbA1c levels) without an increased risk of hypoglycemia, and potentially a simplification of complex insulin regimens, thereby enhancing the quality of life and safety for individuals with diabetes.

Eli Lilly's strategic focus in this innovative area is further highlighted by its acquisition of Protomer Technologies in 2021.[22] Protomer was a preclinical-stage biotechnology company specifically dedicated to developing glucose-responsive insulins that could sense glucose levels and automatically modulate their activity. While the direct lineage of LY-3938577 from Protomer's platform is not explicitly stated in the provided materials, this corporate acquisition signals Lilly's substantial commitment to the field of "smart insulin" technology.

The progression of LY-3938577 into Phase I clinical trials by a leading pharmaceutical company like Eli Lilly marks a noteworthy development in the pursuit of "smart insulins." The concept of glucose-responsive insulin has been a long-held aspiration in diabetes research, with efforts dating back several decades.[22] However, translating this concept into clinically viable therapies has proven exceptionally challenging due to difficulties in achieving the necessary speed and sensitivity of glucose response, ensuring the biocompatibility and stability of the engineered molecules or systems, and overcoming manufacturing complexities.[22] Lilly's decision to advance LY-3938577 into human trials suggests that their proprietary design and technological approach for this candidate are perceived to have a credible pathway to overcoming these historical obstacles. This endeavor represents more than an incremental improvement; it is a pursuit of a potential paradigm shift in insulin therapy, inherently associated with high risk due to its novelty and past challenges in the field, but also with high reward if successful.

The specific terminology "glucose sensing insulin receptor" used to describe the target of LY-3938577 [1] warrants careful consideration. The conventional insulin receptor's activation is primarily ligand-dependent (i.e., upon insulin binding) and is not known to directly sense glucose to modulate its signaling activity once insulin is bound. This suggests that LY-3938577 is likely an engineered insulin molecule (or a conjugate thereof) that incorporates its own glucose-sensing component. This component would then, in a glucose-dependent manner, influence how LY-3938577 interacts with or activates the standard insulin receptor. This model is consistent with many "smart insulin" concepts, which involve modifying the insulin molecule itself, for instance, by conjugating it with glucose-binding moieties, to enable glucose-responsive changes in its activity.[2] The fact that AdisInsight lists the mechanism of action for LY-3938577 as "Undefined mechanism" [3] likely reflects the early stage of its development and the proprietary nature of its detailed molecular engineering, which has not yet been fully elucidated in publicly available scientific literature or regulatory documents.

3. Pharmacological Profile

3.1. Drug Class

LY-3938577 is categorized as an antihyperglycaemic agent, reflecting its intended therapeutic use in lowering elevated blood glucose levels in individuals with diabetes mellitus.[3] Furthermore, it is identified as a "biological product".[4] This classification implies that LY-3938577 is a macromolecule, likely protein or peptide-based, developed through biotechnological processes, rather than a traditional, chemically synthesized small molecule. This aligns with its nature as an engineered insulin or an insulin-like therapeutic.

The designation as a "biological product" has several important implications for its development and potential clinical use. Manufacturing processes for biologics are typically more intricate and costly compared to those for small-molecule drugs. There is also an inherent potential for immunogenicity, wherein the patient's immune system might recognize the biological agent as foreign and mount an immune response. This necessitates careful evaluation during clinical trials. Additionally, the regulatory pathways for the approval of biological products (e.g., a Biologics License Application in the United States) differ from those for small-molecule drugs (e.g., a New Drug Application). These factors are critical considerations throughout the lifecycle of LY-3938577's development. The biological nature of the product is consistent with the sophisticated protein engineering or conjugation strategies that would typically be required to confer glucose-sensing properties upon an insulin molecule.

3.2. Mechanism of Action (MoA)

The proposed mechanism of action for LY-3938577 is centered on its interaction with a "glucose sensing insulin receptor" or its function as a "GS insulin receptor agonist".[1] This suggests that the drug's ability to activate the insulin receptor, and thereby initiate downstream signaling pathways leading to glucose uptake and utilization, is dynamically modulated by the ambient glucose concentration. In principle, higher glucose levels would potentiate its insulin-like activity, while lower glucose levels would attenuate it, thereby creating a self-regulating system designed to minimize the risk of hypoglycemia.

The insulin receptor (INSR, also known as CD220) is a well-established transmembrane tyrosine kinase receptor that plays a pivotal role in glucose homeostasis by mediating the cellular effects of insulin.[36] The innovative aspect of LY-3938577 lies in the "glucose-sensing" capability that is presumably engineered into its design, allowing its interaction with this receptor system to be glucose-dependent.

The term "glucose sensing insulin receptor agonist" [19] offers a more precise insight into its function. An agonist is a molecule that binds to a receptor and triggers a physiological response. This implies that LY-3938577 directly activates the insulin receptor, much like endogenous insulin or conventional insulin analogs, thereby initiating the cascade of intracellular events that lead to glucose disposal (e.g., translocation of GLUT4 glucose transporters, stimulation of glycogen synthesis, and inhibition of gluconeogenesis). The "glucose-sensing" characteristic suggests that the intensity or efficacy of this agonistic activity is not constant but varies according to glucose levels. This could be achieved if, for example, glucose binding to a specific moiety engineered into the LY-3938577 molecule (or a complex of which it is part) induces a conformational change in LY-3938577, which in turn alters its affinity for, or its ability to activate, the insulin receptor. Such a sophisticated mechanism would necessitate advanced molecular engineering.

It is important to note that AdisInsight currently classifies the mechanism of action for LY-3938577 as "Undefined mechanism".[3] This likely reflects the early stage of the drug's development and the proprietary nature of its detailed molecular interactions, which have not yet been fully disclosed by Eli Lilly in peer-reviewed scientific publications or comprehensive regulatory documents.

3.3. Pharmacodynamics (PD)

The primary pharmacodynamic effect anticipated for LY-3938577 is the lowering of blood glucose levels. A crucial objective of the ongoing Phase I clinical trial NCT06280703, particularly Parts B and C of the study, is to meticulously evaluate this glucose-lowering effect and the duration of action of LY-3938577 in participants with Type 1 Diabetes Mellitus.[5] These evaluations will employ euglycemic and hyperglycemic clamp techniques, which are considered the gold-standard methodologies for quantitatively assessing insulin action and sensitivity in humans.

The utilization of these sophisticated clamp techniques in an early-phase (Phase I) study signifies a rigorous and scientifically robust approach by Eli Lilly to characterize the glucose-dependent activity profile of LY-3938577 from the outset of human testing. Euglycemic clamps, for example, involve infusing insulin (or an insulin-like drug) at a constant rate while simultaneously infusing glucose at a variable rate to maintain blood glucose at a normal (euglycemic) level. The rate of glucose infusion required to maintain euglycemia is a direct measure of insulin sensitivity and action. Hyperglycemic clamps, on the other hand, assess insulin secretion in response to a sustained high glucose level; however, when evaluating an exogenous insulin-like agent such as LY-3938577, these clamps would serve to characterize its activity under conditions of elevated glucose.

In the NCT06280703 study, LY-3938577's pharmacodynamic profile will be compared to that of Insulin Degludec, an ultra-long-acting basal insulin analog known for its relatively flat and prolonged action profile, which provides stable basal insulin coverage.[5] This comparison is of paramount importance. If LY-3938577 demonstrates a more pronounced glucose-lowering effect at high glucose concentrations and, conversely, a diminished effect at euglycemic or near-hypoglycemic levels relative to Insulin Degludec (which exhibits a more constant action across varying glucose levels within a certain physiological range), it would provide strong empirical support for its "glucose-sensing" mechanism and its potential clinical advantages in terms of both efficacy and safety.

4. Clinical Development Program

4.1. Overview

LY-3938577 is currently in Phase I of clinical development.[1] The program is investigating the compound for the treatment of both Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).[1] The routes of administration being explored are intravenous (IV) and subcutaneous (SC).[1]

4.2. Summary of Clinical Trials

The following table summarizes key publicly available information on the clinical trials for LY-3938577:

NCT Identifier	Official Trial Title	Phase	Status	Condition(s) Studied	Key Interventions	Primary Purpose(s)	Sponsor	Key Locations	Target Enrollment	Study Start Date	Estimated/Actual Completion Date
NCT06132126	A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus (J4P-MC-IYAA)	Phase I	Completed	Healthy Volunteers, Type 2 Diabetes Mellitus	LY3938577 (SC), Placebo (SC), Insulin degludec (SC)	Safety, Tolerability, PK	Eli Lilly and Company	USA	66	Nov 17, 2023	Jun 28, 2024 (Actual)
NCT06280703	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (J4P-MC-IYAB) / A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C) Study...	Phase I	Recruiting	Healthy Volunteers, Type 1 Diabetes Mellitus	LY3938577 (IV, SC), Placebo (IV, SC), Insulin degludec (IV, SC), Insulin lispro (IV)	Safety, Tolerability, PK, PD (glucose-lowering)	Eli Lilly and Company	Germany	70	May 15, 2024	Oct 2025 (Estimated)

Data synthesized from multiple sources including.[1]

4.3. Detailed Review of Clinical Trial NCT06132126

Official Title: "A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus" (also referred to as "A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus").4

Status: Completed. The primary completion date was June 28, 2024.3 MedPath last updated information on July 24, 2024.5

Sponsor: Eli Lilly and Company.4

Phase: I.1

Brief Summary: The study was designed to assess the safety and tolerability of single doses (Part A) and multiple ascending doses (Part B) of LY-3938577.4

Study Design: This was a single and multiple-ascending dose study with a primary purpose of evaluating safety, tolerability, and pharmacokinetics.4

Participant Population: Healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) were enrolled.4 The target enrollment was 66 participants.5 Key eligibility criteria included general good health for healthy volunteers, a diagnosis of T2DM for at least one year for patients, and stable body weight for at least 90 days prior to screening.13

Interventions:

• Part A (Single Dose): LY3938577 administered subcutaneously (SC), Placebo administered SC, Insulin degludec administered SC.[8]
• Part B (Multiple Doses, T2DM): LY3938577 administered SC.[8] Primary Outcome Measures:
• Assessment of safety and tolerability (e.g., incidence and severity of adverse events).
• Pharmacokinetic parameters of LY-3938577 (e.g., maximum concentration (Cmax​), area under the concentration-time curve (AUC)). Locations: The study was conducted at sites in the United States, including Labcorp CRU in Dallas, TX; Qps-Mra, Llc in Miami, FL; and CenExel ACT in Anaheim, CA.[5] Results/Publications: As of the latest information available (July 2024), the trial has been completed. However, specific results or publications arising from this study have not yet been listed in the public domain.[11]

The completion of the NCT06132126 study represents a critical initial step in the human evaluation of LY-3938577. The data gathered on safety, tolerability, and pharmacokinetics following single and multiple subcutaneous doses in both healthy individuals and patients with T2DM are foundational for Eli Lilly's subsequent development decisions. These findings will directly inform whether the compound is sufficiently safe to proceed to later-phase trials, how it is absorbed and eliminated when administered via the subcutaneous route, and what dose ranges are appropriate for further investigation. Although a direct comparison with insulin degludec was part of the study design, the specifics of this comparison and its outcomes are not yet public. It is standard practice for pharmaceutical companies to conduct thorough analyses of Phase I data before disclosing results, typically at major scientific conferences or in peer-reviewed journals. Therefore, public dissemination of the findings from NCT06132126 may be anticipated in late 2024 or 2025.

4.4. Detailed Review of Clinical Trial NCT06280703

Official Title: "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)" (also referred to as "A Three-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B and Part C), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus").4

Status: Recruiting.2 The estimated study completion date is October 2025.12

Sponsor: Eli Lilly and Company.4

Phase: I.2

Brief Summary: The study aims to evaluate the pharmacokinetics (absorption and elimination of LY-3938577), pharmacodynamics (glucose-lowering effect and duration of action, compared to Insulin Degludec in T1DM patients), safety, and tolerability of LY-3938577.5

Study Design: This is a three-part (A, B, and C) study. Part A is randomized and double-blind (LY-3938577 versus Placebo). Parts B and C are open-label. The study incorporates multi-dose elements and is primarily designed for basic science (PK/PD characterization), as well as safety and tolerability assessment.4

Participant Population: Healthy participants will be enrolled in Part A, while participants with T1DM will be enrolled in Parts B and C. The target enrollment is 70 participants, aged 18 to 64 years.4

* Eligibility Criteria 5:

* Part A (Healthy Volunteers): Overtly healthy individuals as determined by medical history and physical examination.

* Parts B and C (T1DM Participants): Established diagnosis of T1DM for at least 2 years; fasting C-peptide level ≤ 0.20 nmol/L (or non-fasting C-peptide level ≤ 0.30 nmol/L) at screening; HbA1c between 6.0% and 8.5% (inclusive); if using an insulin pump, total daily basal dose between 15 and 45 International Units (IU).

* All Parts: Normal blood pressure and pulse rate; safety laboratory test results acceptable for the study; Body Mass Index (BMI) between 18.0 and 35.0 kg/m$^2$ (inclusive) at screening; adequate venous access for blood sampling; male participants or female participants not of childbearing potential.

* Key Exclusion Criteria (All Parts): Recent (within 3 months) treatment with GLP-1 Receptor Agonists (GLP1-RA), Dipeptidyl Peptidase 4 (DPP4) inhibitors, Glucose-dependent Insulinotropic Polypeptide (GIP) agonists, Metformin, or Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors; history of renal transplantation, currently receiving renal dialysis, serum creatinine level >2.00 mg/dL, or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m$^2$; acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease (excluding non-alcoholic fatty liver disease, NAFLD), and/or elevated liver enzyme measurements (Total bilirubin (TBL) >2 times the Upper Limit of Normal (ULN) in the absence of Gilbert's syndrome, or Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) >2.5 times ULN, or Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) >2.5 times ULN).

Interventions 5:

• Part A Period 1 (Healthy Participants): Single intravenous (IV) dose of LY3938577 or Placebo.
• Part A Period 2 (Healthy Participants): Single subcutaneous (SC) dose of LY3938577 or Placebo.
• Part B (T1DM Participants): Single IV doses of LY3938577 or Insulin Degludec. These administrations will occur during euglycemic and hyperglycemic clamp procedures, with Insulin Lispro administered at a constant low rate to cover the individual participant's basal (fasting) insulin demand and maintain stable glucose levels during the clamps.
• Part C (T1DM Participants): Two SC doses of LY3938577 or Insulin Degludec. Primary Outcome Measures [5]:
• Pharmacokinetics of LY-3938577 (e.g., Cmax​, AUC).
• Number of participants experiencing adverse events. Secondary Outcome Measures [5]:
• Pharmacodynamic parameters related to glucose control (e.g., glucose infusion rate during clamp procedures, changes in blood glucose levels). Locations: Germany (Profil Institut für Stoffwechselforschung, Neuss).[5] Results/Publications: This trial is currently in the recruiting phase; therefore, no results or publications are available at this time.

The design of the NCT06280703 study is particularly crucial for understanding the potential of LY-3938577. The inclusion of both healthy volunteers (for initial safety and PK assessment of IV and SC routes) and individuals with T1DM (for detailed PD assessment) is comprehensive for a Phase I study. The incorporation of euglycemic and hyperglycemic clamp procedures in T1DM participants is a rigorous method to directly quantify insulin action and, critically, to assess the glucose-responsiveness of LY-3938577. By comparing its pharmacodynamic profile under these controlled conditions against Insulin Degludec, a well-established ultra-long-acting basal insulin, researchers aim to determine if LY-3938577 can indeed offer a more physiological, "smarter" insulin action. The focus on T1DM, a condition characterized by absolute insulin deficiency, will allow for a clearer evaluation of LY-3938577's intrinsic properties without the confounding variables of endogenous insulin secretion or significant insulin resistance often present in T2DM.

4.5. Regulatory Status and Designations

Based on the available information, LY-3938577 has not received any specific regulatory designations, such as Orphan Drug Designation, from major regulatory authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).[4] Given that T1DM and T2DM are prevalent conditions, Orphan Drug Designation would generally not be applicable unless the drug were being developed for a very specific, rare sub-population within diabetes, which is not indicated by the current broad trial designs. Standard interactions with regulatory agencies regarding the overall development plan are an ongoing part of any drug development program but are not typically made public at this early stage.

4.6. Patents

While Eli Lilly and Company holds numerous patents in the field of diabetes and insulin technology, specific patent documents that definitively cover the exact molecular structure or composition of LY-3938577 are not explicitly identified or detailed in the provided research materials.[2] Some patent applications, such as WO2015051052A2/A3 and WO2016179568A1, discuss glucose-responsive insulin conjugates generally.[30] However, their direct and specific linkage to the LY-3938577 clinical candidate is not confirmed by the available information. The proprietary nature of novel drug candidates often means that specific structural and compositional patent details become fully public or are definitively linked to a development code (like LY-3938577) at a later stage in the development process, often after more substantial clinical data has been generated.

4.7. Conference Presentations

As of the information available up to early 2025, there are no specific conference presentations (e.g., at the American Diabetes Association (ADA) Scientific Sessions, the European Association for the Study of Diabetes (EASD) Annual Meeting, the Endocrine Society's ENDO meeting, or the Advanced Technologies & Treatments for Diabetes (ATTD) Conference) that detail clinical trial results for LY-3938577.[16] This is consistent with the early phase of its clinical development program. Pharmaceutical companies typically present Phase I data after the study's completion and thorough internal analysis, often choosing major scientific meetings for initial disclosure.

The current lack of detailed structural patents specifically linked to LY-3938577 or specific conference presentations detailing its clinical results by mid-2024/early-2025, despite Phase I trials being active or completed, is characteristic of the early stages of pharmaceutical development. Companies typically maintain stringent control over proprietary information regarding novel drug candidates until more substantial clinical data packages are assembled or strategic public disclosures are planned.

5. Chemical and Physical Properties

LY-3938577 is also identified by the alternative name LY3938577 in various development and trial tracking databases.[5]

As a biological product [4], detailed chemical and physical properties such as a specific CAS (Chemical Abstracts Service) registry number, a definitive molecular formula, and an exact molecular weight are not publicly available in the provided research materials.[4] Similarly, the precise amino acid sequence (if it is a peptide or protein) or detailed structural information of this engineered biological molecule has not been disclosed in the public domain.[4]

The absence of such specific chemical identifiers and detailed structural information is a common characteristic for proprietary biological therapeutics that are in the early phases of clinical development. This type of information is typically guarded by the developing company and is often revealed at later stages of development, such as in comprehensive patent disclosures that can be definitively linked to the specific clinical candidate, or in detailed scientific publications following the release of more mature clinical data.

6. Preclinical Data

Specific preclinical study results for LY-3938577, such as in vitro characterizations of its glucose-sensing mechanism or detailed efficacy and safety data from animal models of diabetes, are not extensively detailed in the publicly available research snippets.[7]

While the broader concept of glucose-responsive insulins has been an area of active preclinical research by various academic groups and pharmaceutical companies—including Eli Lilly, notably through its acquisition of Protomer Technologies which was focused on such agents [2]—the specific preclinical data package that supported the Investigational New Drug (IND) application and initiation of human trials for LY-3938577 itself is not publicly accessible. It is standard practice for pharmaceutical companies to compile an extensive internal preclinical dossier demonstrating proof-of-concept for the mechanism of action, efficacy in relevant disease models, and an acceptable safety profile in toxicology studies before advancing a candidate into Phase I clinical trials. The limited public availability of specific preclinical data for LY-3938577 is typical for a compound at this stage, as the focus of public disclosure begins to shift towards emerging human data from the initial clinical studies.

7. Discussion and Future Outlook

LY-3938577 represents a potentially transformative therapeutic approach within the field of diabetes management. Its development by Eli Lilly and Company as a glucose-sensing insulin receptor agonist directly addresses a long-standing ambition in diabetology: to create an insulin therapy that can autonomously adjust its biological activity in response to real-time fluctuations in blood glucose levels. If successfully realized, this could offer individuals with both Type 1 and Type 2 diabetes a more physiological method of glycemic control, a significantly reduced risk of debilitating and dangerous hypoglycemia, and an overall simplification of the daily burdens associated with diabetes management.

The progression of LY-3938577 through Phase I clinical trials, particularly the ongoing NCT06280703 study with its rigorous pharmacodynamic assessments (utilizing euglycemic and hyperglycemic clamp techniques), will be pivotal in validating its proposed glucose-sensing mechanism of action. The data emerging from these initial human studies will provide the first critical insights into whether the glucose-responsive properties, hypothesized or observed in preclinical settings, translate into a clinically meaningful and safe effect in humans. Key parameters of interest will include the sensitivity and responsiveness of LY-3938577 across a range of glucose concentrations, its pharmacokinetic profile (including duration of action), and its overall safety and tolerability.

The development of "smart insulins" has historically been a complex endeavor, marked by significant scientific and technical challenges. These have included the difficulty in designing molecules or systems that can accurately and rapidly sense physiological glucose changes, modulate insulin activity appropriately across the full glycemic spectrum, maintain stability and biocompatibility, avoid immunogenicity, and be amenable to scalable and cost-effective manufacturing. Eli Lilly's decision to advance LY-3938577 into clinical trials suggests a degree of confidence that their specific molecular design and technological approach may have overcome some of these substantial historical hurdles. The company's acquisition of Protomer Technologies in 2021 further underscores a strategic commitment to this innovative therapeutic space.[22]

The competitive landscape in diabetes therapeutics is intensely dynamic, with continuous advancements in conventional insulin formulations, GLP-1 receptor agonists, SGLT2 inhibitors, dual and triple agonists (like tirzepatide and retatrutide from Lilly's own pipeline), and other novel mechanisms. For LY-3938577 to carve out a significant clinical niche, it will need to demonstrate clear and compelling advantages over existing and emerging treatment options. These advantages would likely need to be most prominent in the domains of safety (particularly a markedly reduced incidence of hypoglycemia) and improved glycemic control metrics (such as increased time-in-range and HbA1c reduction without a corresponding increase in hypoglycemic events). While other companies, such as Novo Nordisk with research compounds like NNC2215 [20], are also exploring glucose-sensitive insulin technologies, the direct competitive positioning will only become apparent as more substantial clinical data for LY-3938577 and other similar agents become available.

The successful clinical development and eventual regulatory approval of LY-3938577 could profoundly alter the treatment paradigm for diabetes. For individuals with T1DM, it could offer a basal insulin replacement that inherently adapts to metabolic changes, potentially leading to greater stability in glucose levels, reduced fear of hypoglycemia, and an overall improvement in disease management and quality of life. For many individuals with T2DM who require insulin, it could provide a safer, more effective, and potentially simpler insulin option, particularly for those prone to hypoglycemia or those who struggle with complex titration regimens. However, the path to bringing such a novel biological therapeutic to market is long and fraught with challenges. Beyond demonstrating robust efficacy and safety in larger and longer-duration Phase II and III clinical trials, Eli Lilly will also need to address aspects related to scalable and cost-effective manufacturing, and clearly establish the value proposition of LY-3938577 to patients, healthcare providers, and payers.

8. Conclusion

LY-3938577 is an early-stage investigational biological product, developed by Eli Lilly and Company, which is being evaluated as a glucose-sensing insulin receptor agonist for the treatment of both Type 1 and Type 2 Diabetes Mellitus. The core innovation of this therapeutic candidate lies in its potential to provide glucose-responsive insulin activity, thereby aiming to optimize glycemic control while significantly minimizing the risk of hypoglycemia, a critical unmet need in current diabetes management.

Currently advancing through Phase I clinical development, with one study (NCT06132126) recently completed and another (NCT06280703) actively recruiting and incorporating detailed pharmacodynamic assessments, LY-3938577 is at a crucial stage. The forthcoming results from these initial human trials will be paramount in determining its safety, tolerability, and pharmacokinetic profile. Most importantly, these studies will provide the first clinical evidence as to whether its engineered glucose-sensing mechanism translates into a tangible and differentiated therapeutic effect in humans.

While the development of "smart insulins" has historically faced considerable challenges, the potential benefits for individuals living with diabetes are substantial. The commitment of a major pharmaceutical innovator like Eli Lilly to this advanced therapeutic concept underscores the potential significance of the LY-3938577 program. Future disclosures of clinical trial outcomes and further elucidation of its precise molecular mechanism of action will be critical in shaping the future trajectory and therapeutic promise of LY-3938577.

References

• [1]: GlobalData. Likelihood of Approval and Phase Transition Success Rate Model - LY-3938577 in Type 2 Diabetes.
• [2]: Pharmaceutical Technology. LY-3938577 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval.
• [3]: AdisInsight. LY 3938577. (09 Aug 2024).
• [7]: Lilly Trials. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM).
• [56]: Pharmaceutical Technology. Data Insights.
• [36]: ACROBiosystems. Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified).
• [8]: Veeva CTV. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus.
• [6]: Clinical Digest. Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials. (20 May 2025).
• [9]: DrugBank. Type 2 Diabetes Completed Phase 1 Trials for Insulin degludec (DB09564).
• [4]: Synapse by PatSnap. LY-3938577 - Drug Targets, Indications, Patents.
• [5]: MedPath. LY-3938577.
• [10]: Veeva CTV. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM).
• [37]: ACROBiosystems. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified).
• [3]: AdisInsight. LY 3938577. (09 Aug 2024).
• [19]: PhRMA. Medicines in Development: Preventive Treatments. (September 15, 2024).
• [47]: Patents.google.com. US20210069286A1 - Compositions and methods for treating hyperglycemia and associated conditions.
• [1]: GlobalData. Likelihood of Approval and Phase Transition Success Rate Model - LY-3938577 in Type 2 Diabetes.
• [54]: Lilly Medical. EASD 2024 Presentations. (September 10, 2024).
• [55]: Lilly Medical. EASD 2023 Presentations. (October 2, 2023 - October 6, 2023).
• [48]: The Motley Fool. Eli Lilly (LLY) Q4 2023 Earnings Call Transcript. (February 6, 2024).
• [49]: Investing.com. Earnings Call: Eli Lilly Reports Robust Growth and Pipeline Progress. (February 7, 2024).
• [50]: DrugPatentWatch. Eli Lilly And Company - Patents by Applicant.
• [14]: DrugBank. Type 1 Diabetes Mellitus (DBCOND0029465).
• [41]: Lilly Investor Relations. Q1 2024 Earnings Presentation.
• [30]: Patents.google.com. WO2015051052A2 - Glucose-responsive insulin conjugates.
• [35]: Patents.google.com. WO2015051052A3 - Glucose-responsive insulin conjugates.
• [38]: ACROBiosystems. Insulin R Protein.

Works cited

1. Likelihood of Approval and Phase Transition Success Rate Model - LY-3938577 in Type 2 Diabetes - Market Research Reports & Consulting - GlobalData, accessed May 26, 2025, https://www.globaldata.com/store/report/ly-3938577-in-type-2-diabetes-loa-innovation-and-trend-analysis/
2. LY-3938577 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval, accessed May 26, 2025, https://www.pharmaceutical-technology.com/data-insights/ly-3938577-eli-lilly-and-co-type-2-diabetes-likelihood-of-approval/
3. LY 3938577 - AdisInsight - Springer, accessed May 26, 2025, https://adisinsight.springer.com/drugs/800076226
4. LY-3938577 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 26, 2025, https://synapse.patsnap.com/drug/1cb66c9e0ca94460b15fb4b2ba6eca6e
5. LY-3938577 - MedPath, accessed May 26, 2025, https://trial.medpath.com/drug/f05bf474d0486f06
6. Clinical Digest: A Comprehensive Review of Recent Eli Lilly Clinical Trials, accessed May 26, 2025, https://resources.clinicaldigest.org/2025/05/20/clinical-digest-a-comprehensive-review-of-recent-eli-lilly-clinical-trials/
7. Find Lilly Clinical Trials, accessed May 26, 2025, https://trials.lilly.com/en-US/find
8. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus - ClinicalTrials.Veeva, accessed May 26, 2025, https://ctv.veeva.com/study/a-study-to-investigate-the-safety-and-tolerability-of-ly3938577-in-healthy-participants-and-particip
9. Type 2 Diabetes Completed Phase 1 Trials for Insulin degludec (DB09564) - DrugBank, accessed May 26, 2025, https://go.drugbank.com/indications/DBCOND0030616/clinical_trials/DB09564?phase=1&status=completed
10. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) - ClinicalTrials.Veeva, accessed May 26, 2025, https://ctv.veeva.com/study/a-study-of-ly3938577-in-healthy-participants-and-participants-with-type-1-diabetes-mellitus-t1dm
11. Insulin degludec | MedPath, accessed May 26, 2025, https://trial.medpath.com/drug/d75d5bf9ac9b9987
12. A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) - Lilly Trials, accessed May 26, 2025, https://trials.lilly.com/en-US/trial/465015
13. A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus - Lilly Trials, accessed May 26, 2025, https://trials.lilly.com/en-US/trial/436457
14. Type 1 Diabetes Mellitus (DBCOND0029465) | DrugBank Online, accessed May 26, 2025, https://go.drugbank.com/conditions/DBCOND0029465
15. Novo Nordisk Trials - LARVOL Sigma, accessed May 26, 2025, https://sigma.larvol.com/company.php?e1=9900&e2=&sourcepg=TZC&tab=OTTtrac&sr=now&er=1+month&ipwnd=on&rlink=,tab=OTTtrac,sourcepg=TZC,itype=0,1&rflag=1&page=4
16. q1 2025 earnings call - Eli Lilly Investors, accessed May 26, 2025, https://investor.lilly.com/static-files/761fadb8-b911-46d5-85b3-8bac4e054d73
17. Earnings Presentation - Eli Lilly Investors, accessed May 26, 2025, https://investor.lilly.com/static-files/09d156c0-f88d-420b-b5f1-1ed2b417461b
18. q1 2025 earnings call - Public now, accessed May 26, 2025, https://docs.publicnow.com/viewDoc.aspx?filename=33758\EXT\06B2B741D8215516BCDB3E1DFF0F3279C8F4716D_761F2A006B4C9766878BF8E7E77278AE7D52EFCF.PDF
19. Medicines in Development − Preventive Treatment and Chronic Diseases, accessed May 26, 2025, https://phrma.mrmdigital.com/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/MID-Reports/MID_Preventive_Treatments_Drug-List.pdf
20. (PDF) Glucose-sensitive insulin with attenuation of hypoglycaemia - ResearchGate, accessed May 26, 2025, https://www.researchgate.net/publication/384973740_Glucose-sensitive_insulin_with_attenuation_of_hypoglycaemia
21. New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals, accessed May 26, 2025, https://academic.oup.com/jcem/article-pdf/107/4/909/42995966/dgab849.pdf
22. Lilly wagers up to $1B on a biotech's plan for a new type of insulin | BioPharma Dive, accessed May 26, 2025, https://www.biopharmadive.com/news/lilly-acquire-protomer-glucose-sensitive-insulin/603325/
23. Eli Lilly | Drug Developments | Pipeline Prospector - PharmaCompass.com, accessed May 26, 2025, https://www.pharmacompass.com/pipeline-prospector-drugs-in-development/eli-lilly
24. Eli Lilly gets glucose-sensing "smart insulin" via buyout of preclinical Protomer, accessed May 26, 2025, https://medcitynews.com/2021/07/eli-lilly-gets-glucose-sensing-smart-insulin-via-buyout-of-preclinical-protomer/
25. What are the key players in the Type 1 diabetes treatment market?, accessed May 26, 2025, https://synapse.patsnap.com/article/what-are-the-key-players-in-the-type-1-diabetes-treatment-market
26. www.novonordisk.com, accessed May 26, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf
27. MidgardFinance.com -, accessed May 26, 2025, https://blog.midgardfinance.com/
28. $1.9 50+ 300K - Breakthrough T1D Canada, accessed May 26, 2025, http://breakthrought1d.ca/wp-content/uploads/2024/02/Annual_Report_2014_Eng.pdf
29. Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead, accessed May 26, 2025, https://diabetesresearch.org/wp-content/uploads/2024/09/s41574-024-01029-0.pdf
30. WO2015051052A2 - Glucose-responsive insulin conjugates - Google Patents, accessed May 26, 2025, https://patents.google.com/patent/WO2015051052A2/en
31. 'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues - PMC - PubMed Central, accessed May 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8158166/
32. (PDF) IMRA Conference Proceedings - ResearchGate, accessed May 26, 2025, https://www.researchgate.net/publication/289520132_IMRA_Conference_Proceedings
33. (PDF) Emerging Technologies for Diabetes Care - ResearchGate, accessed May 26, 2025, https://www.researchgate.net/publication/325867356_Emerging_Technologies_for_Diabetes_Care
34. Lilly reports first-quarter 2025 financial results and highlights pipeline momentum, accessed May 26, 2025, https://investor.lilly.com/node/52321/pdf
35. WO2015051052A3 - Glucose-responsive insulin conjugates - Google Patents, accessed May 26, 2025, https://patents.google.com/patent/WO2015051052A3/en
36. Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified), accessed May 26, 2025, https://www.acrobiosystems.com/P2778-Human-Insulin-R--CD220-%2828-944%29-Protein-His-Tag-%28MALS--SPR-verified%29.html
37. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified), accessed May 26, 2025, https://es.acrobiosystems.com/P6845-Biotinylated-Human-Insulin-R--CD220-%2828-944%29-Protein-HisAvitag%E2%84%A2-%28MALS--SPR-verified%29.html
38. Insulin R Protein | ACROBiosystems, accessed May 26, 2025, https://www.acrobiosystems.com/L-333-Insulin%20R.html
39. Human Insulin R / CD220 (28-944) Protein, His Tag (MALS & SPR verified) - ACROBiosystems, accessed May 26, 2025, https://es.acrobiosystems.com/P2778-Human-Insulin-R--CD220-%2828-944%29-Protein-His-Tag-%28MALS--SPR-verified%29.html
40. Biotinylated Human Insulin R / CD220 (28-944) Protein, His,Avitag™ (MALS & SPR verified), accessed May 26, 2025, https://www.acrobiosystems.com/P6845-Biotinylated-Human-Insulin-R--CD220-%2828-944%29-Protein-HisAvitag%E2%84%A2-%28MALS--SPR-verified%29.html
41. Eli Lilly and Company Q1 2024 Earnings Call, accessed May 26, 2025, https://investor.lilly.com/static-files/d0789b60-5579-415e-9461-8b8130413dd6
42. Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue, Trial ID 417-201-00060 - Otsuka Clinical Trials, accessed May 26, 2025, https://trials.otsuka-us.com/trials/417-201-00060
43. Eli Lilly's Oral GLP-1 Shows Positive Results for Type 2 Diabetes - HIT Consultant, accessed May 26, 2025, https://hitconsultant.net/2025/04/17/lillys-oral-glp-1-shows-positive-phase-3-results-for-type-2-diabetes/
44. Eli Lilly and Company Q1 2024 Earnings Call - Public now, accessed May 26, 2025, https://docs.publicnow.com/viewDoc.aspx?filename=33758\EXT\F0314EC9E09625250C128427E741F0EF5CF7C7E3_6C06EAD064D3E6A4CB97580A984C9880E5CB7AC1.PDF
45. Medicines | European Medicines Agency (EMA), accessed May 26, 2025, https://www.ema.europa.eu/en/medicines
46. Drug Approvals and Databases | FDA, accessed May 26, 2025, https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
47. US20210069286A1 - Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage - Google Patents, accessed May 26, 2025, https://patents.google.com/patent/US20210069286A1/en
48. Eli Lilly (LLY) Q4 2023 Earnings Call Transcript | The Motley Fool, accessed May 26, 2025, https://www.fool.com/earnings/call-transcripts/2024/02/06/eli-lilly-lly-q4-2023-earnings-call-transcript/
49. Earnings call: Eli Lilly reports robust growth and pipeline progress - Investing.com, accessed May 26, 2025, https://www.investing.com/news/stock-market-news/earnings-call-eli-lilly-reports-robust-growth-and-pipeline-progress-93CH-3294688
50. LILLY drug patent status, global patents, accessed May 26, 2025, https://www.drugpatentwatch.com/p/applicant/Lilly
51. WO2016179568A1 - Glucose responsive insulins - Google Patents, accessed May 26, 2025, https://patents.google.com/patent/WO2016179568A1/en
52. Eli Lilly & Co. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed May 26, 2025, https://synapse.patsnap.com/organization/2f55b324e0e20f9411ed3667550d0ba7
53. Q3 2024 Lilly Presentation, accessed May 26, 2025, https://investor.lilly.com/static-files/cdedba2e-c4a7-4047-9e61-4ac3b1e2cd73
54. Welcome to the Lilly Scientific Information Page for EASD 2024, accessed May 26, 2025, https://medical.lilly.com/us/science/conferences/diabetes/easd2024
55. Welcome to Lilly Scientific Information Page for EASD 2023, accessed May 26, 2025, https://medical.lilly.com/us/science/conferences/diabetes/easd
56. Data Insights - Pharmaceutical Technology, accessed May 26, 2025, https://www.pharmaceutical-technology.com/data-insights/
57. Elucidating the pharmacogenetics of the response to GLP-1 receptor agonists for type 2 diabetes - NIH RePORTER, accessed May 26, 2025, https://reporter.nih.gov/project-details/10839451
58. Completed Trials - Lilly Trials, accessed May 26, 2025, https://trials.lilly.com/en-US/find/completed
59. International Clinical Trials Registry Platform (ICTRP) - World Health Organization (WHO), accessed May 26, 2025, https://www.who.int/tools/clinical-trials-registry-platform
60. ICTRP search portal - World Health Organization (WHO), accessed May 26, 2025, https://www.who.int/tools/clinical-trials-registry-platform/the-ictrp-search-portal
61. clinicaltrials.gov, accessed May 26, 2025, https://clinicaltrials.gov/study/NCT06132126
62. clinicaltrials.gov, accessed May 26, 2025, https://clinicaltrials.gov/study/NCT06280703
63. Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis - PubMed Central, accessed May 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11857078/
64. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial - PubMed, accessed May 26, 2025, https://pubmed.ncbi.nlm.nih.gov/36354040/
65. GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes | ACS Pharmacology & Translational Science, accessed May 26, 2025, https://pubs.acs.org/doi/10.1021/acsptsci.4c00173
66. accessed January 1, 1970, httpsisinsight.springer.com/drugs/800076226
67. accessed January 1, 1970, https://www.lillytrials.com/en-US/find/NCT06132126
68. accessed January 1, 1970, https://www.lillytrials.com/en-US/find/NCT06280703
69. accessed January 1, 1970, https://investor.lilly.com/static-files/some-recent-lilly-investor-presentation.pdf
70. accessed January 1, 1970, https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2024-financial
71. accessed January 1, 1970, https://www.ema.europa.eu/en/medicines/search_medicines
72. accessed January 1, 1970, https://www.accessdata.fda.gov/scripts/cder/daf/
73. accessed January 1, 1970, https://investor.lilly.com/events-and-presentations/events
74. accessed January 1, 1970, https://professional.diabetes.org/abstracts-archive
75. EASD 2024 | EASD, accessed May 26, 2025, https://www.easd.org/annual-meeting/easd-2024.html
76. accessed January 1, 1970, https://investor.lilly.com/financials/annual-reports
77. accessed January 1, 1970, https://investor.lilly.com/events-and-presentations
78. accessed January 1, 1970, https://apps.who.int/trialsearch/
79. accessed January 1, 1970, https://trialsearch.who.int/TrialSearch.aspx?query=LY-3938577
80. accessed January 1, 1970, https://trialsearch.who.int/TrialSearch.aspx?query=LY3938577